STUDIES ON HUMAN PLASMA α2-MACROGLOBULIN-ENZYME INTERACTIONS : EVIDENCE FOR PROTEOLYTIC MODIFICATION OF THE SUBUNIT CHAIN STRUCTURE by Harpel, Peter C.
STUDIES  ON  HUMAN  PLASMA  a2-MACROGLOBULIN-ENZYME 
INTERACTIONS 
EVIDENCE  :FOR PROTEOLYTIC  MODIFICATION  OF  THE  SUBUNIT 
CHAIN  STRUCTURE*' ~ 
BY PETER C. HARPEL 
(From the Departn;ent of Medicine, Division of Hematology, The New York 
Hospital-Cornell Medical Center, New York 10021) 
(Received for publication  16 May 1973) 
The nature  of  the  molecular interactions which occur between circulating 
proteolytic enzymes and their plasma inhibitors is not fully understood. One 
such  inhibitor,  ~z2-macroglobulin,  appears  to  participate  in  the  regulation of 
several  circulating  enzvme  systems,  since  it  forms  a  complex  with  plasmin 
(1-4),  thrombin  (5-7),  and  kallikrein  (8-10).  In  addition,  a2-macroglobulin 
has been found to bind trypsin (11,  12), chymotrypsin (11,  13),  elastase  (14), 
papain,  cationic aspartate  aminotransferase (13),  and subtilisin A  (15). After 
the  formation  of  a  complex  with  a~_-macroglobulin  the  active  site  of  these 
enzymes is not fully inhibited since the bound enzymes retain their ability to 
degrade  small  molecular weight  substrates  but  have  diminished  proteolytic 
activitv. 
In contrast to the paucity of information concerning the mechanisms under- 
lying  the  action  of plasma  proteotytic enzyme inhibitors,  the  interaction  of 
trypsin  with soybean  trypsin inhibitor  as  well  as  a  variety of other protein 
trypsin inhibitors of nonplasma  origin  has  been  extensively studied.  Tryptic 
hydrolysis of a single peptide bond located within a disulfide-bridged loop on 
the inhibitor molecule (16)  appears to be a constant feature of the trypsin in- 
hibitor reaction. This observation has led to the concept that protein inhibitors 
of trypsin may all have a similar susceptible peptide bond and that attack at 
this site is necessary for complex formation and enzyme inhibition (17). 
The potential importance of a2-macroglobulin in regulating hemostatic and 
inflammatory reactions and its  apparently unique enzyme-binding properties 
prompted the present studies.  The effect of the proteases  trypsin,  thrombin, 
plasmin, plasma kallikrein, and chymotrypsin on the covalent structure of a2- 
macroglobulin has been examined. The results indicate that complex formation 
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between  these  enzymes  and  a2-macroglobulin  is  accompanied  by  proteolytic 
modifications in the subunit  chain structure  of the inhibitor. 
Materials  and Methods 
All chemicals  used were reagent grade. Tosyl arginine methyl ester  (TAMe) 1 and  N-a- 
acetylglycyl-L-lysine methyl  ester  acetate  (AGLMe)  were  obtained  from  Cyclo Chemical, 
Division Travenol  Laboratories,  Inc.,  Costa  Mesa,  Calif.  and  benzoyl-DL-arginine-p-nitro- 
anilide (BAPNA) from Mann  Research Laboratories,  Inc., New York.  Soybean trypsin  in- 
hibitor  (grade  SI), pancreatic  trypsin  inhibitor  (grade PSIF),  lima bean  trypsin  inhibitor, 
bovine  trypsin  (grade  TRL),  diisopropylftuorophosphate-  (DFP)  inactivated  trypsin  and 
chymotrypsin (grade WCDS) were obtained from Worthington Biochemical Corp., Freehold, 
N. J. Dithiothreitol (DTT) was obtained from Calbiochem, San Diego, Calif. ; sodium dodecyl 
sulfate (SDS) from Sigma Chemical Co., St. Louis, Mo.; and urokinase from Abbott Labora- 
tories, North Chicago, Ill. 
ce2-macroglobulin was prepared  from human  plasma  by a  modification of previously de- 
scribed methods (8). Venous blood was collected from normal donors into plastic containers 
to minimize activation of the Hageman factor (Factor XII). One part anticoagulant containing 
soybean trypsin inhibitor (0.5 mg/ml of 3.8% sodium citrate) was added to nine parts whole 
blood.  The plasma was harvested after centrifugation at 2,000  )< g for 15 rain at 4°C. After 
adsorption of the prothrombin complex with barium chloride and barium sulfate, the adsorbed 
plasma was precipitated with polyethylene glycol (average molecular weight 3,000  4,000)  to a 
final concentration of 12%  (Matheson, Coleman, and Bell, East Rutherford, N. J.)  (8). The 
low  density  lipoproteins were  then  removed  by  ultracentrifugation  in  potassium  bromide 
(Sp g  1.071). The a2-macroglobulin was further purified by DEAE-cellulose chromatography 
(DE-52, H. Reeve Angel and Co., Inc., Clifton, N. J.) using a linear sodium chloride gradient 
at  constant pH  (starting  buffer,  Tris-HC1 0.05M,  pH 8.0,  and  the limit  buffer  containing 
0.4M NaC1),  gel filtration chromatography  (Bio-Gel A-1.5m,  and  A-5m,  Bio-Rad  Labora- 
tories, Richmond,  Calif.)  and  preparative Pevicon block electrophoresis  (Mercer Chemical 
Corp.,  New  York)  (18).  The  final a2-macroglobulin  fraction  contained  no  other  proteins 
identifiable by double diffusion  analysis using polyvalent rabbit antihuman  serum antibody. 
a2-macroglobulin was also purified from plasma which had been incubated 1 h at 37°C with 
the plasminogen activator, urokinase (500 U/ml plasma). Determination of the concentration 
of a2-macroglobulin preparations was performed by radial imnmnodiffusion (Hyland Immuno- 
Plate  ®, Division Travenol Laboratories, Inc., Costa Mesa, Calif.)  (4). 
lluman Enzymes.--Partially  purified human plasma kallikrein was prepared  as described 
(8). This material was free of both plasmin and thrombin. Purified human thrombin (Lot H-l, 
180 NIH units per vial) was provided by Dr. David Aronson, Bureau of Biologics, Food and 
Drug Administration,  Rockville, Md.  Thrombin-free human  plasmin  (77  caseinolytic units 
per milliliter), spontaneously activated in 50% glycerol, was obtained from the Michigan Dept. 
Public Health, Lansing, Mich. 
The specific  activity  of the trypsin  preparations  used  was experimentally determined  by 
titration with soybean trypsin inhibitor (19) using the substrate  BAPNA (20). The activity 
of  plasmin  preparations  was  assayed  by  a  standard  caseinolytic  assay  (21);  and  that 
of kallikrein by its TAMe esterase activity (l U of activity equaling that volume of enzyme 
which hydrolyzed 1 #mol TAMe per min)  (8). The functional capacity of c~2-macroglobulin 
preparations to form a complex with each of these enzymes was assessed  by determining the 
i Abbreviations  used in this paper: A GLMe, N-ce-acetylglycyl-L-lysine  methyl ester acetate; 
BAPNA,  benzoyl-DL-arginine-p-nitroani]ide;  DFP,  diisopropylfluorophosphate;  DTT, 
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residual enzymic activity of a mixture of cz2-macroglobulin and enzyme against small molecular 
weight substrates after the addition of soybean trypsin inhibitor. This test system reflected 
the presence of enzyme bound in the a2-macroglobulin-enzyme complex  and therefore pro- 
tected from inhibition by soybean trypsin inhibitor (3). The substrates used were BAPNA 
for trypsin (20), AGLMe for plasmin (4), and TAMe for ka]likrein (8). Since thrombin is not 
inhibited by soybean trypsin inhibitor (22), the ability of ot2-macroglobulin to complex with 
this enzyme was determined by its ability to inhibit the fibrinogen  clotting activity of thrombin 
after preincubation with o~2-macroglobulin for 1 h at 37°C (23). 
For  the present studies, a2-macroglobulin was incubated with thrombin, plasmin, and 
kallikrein in concentrations (detailed in Fig. 3 legend) which were completely bound by the 
inhibitor. Thus, after complex formation, no free enzyme could be identified. In the case of 
trypsin, the maximum molar binding capacity of the a~-macroglobulin preparations for the 
enzyme was experimentally determined as described by Ganrot (24). Each mole of as-macro- 
globulin was found to bind 1.3-1.7  mol of trypsin, a ratio consistent with previously deter- 
mined values (25, 26). The molar concentrations of the other proteases examined were esti- 
mated from their proteolytic activity, their reported molecular weight and maximum specific 
activity (27-29). 
Mixtures of purified a2-macroglobulin and the various proteolyfic enzymes were incubated 
at 37°C  in buffer (Tris-HCl 0.05M, pH 8.0,  containing 0.85% sodium chloride and 0.16% 
sodium citrate) in the concentrations indicated in the figure legends. The reaction was stopped 
by adding the mixture to an equal volume of a solution containing 10M urea, 1% SDS and 
14 mM DTT. Mter incubation for 45 rain at 37°C, the reduced ~2-macroglobulin incubation 
mixtures were analyzed by electrophoresis  in polyacrylamide gels containing sodium dodecyl 
sulfate  (30). The protein bands were  stained with Coomassie  brilliant blue. Densitometric 
scans of the gels were carried out in a Gilford model 240 spectrophotometer (Gilford Instru- 
ment Laboratories, Inc., Oberlin, Ohio),  equipped with a linear transport device. 
The molecular weight of the ag,-macroglobulin subunit chain and the proteolytic derivatives 
resulting from  interaction with  the  various enzymes studied  was  determined  by  SDS- 
polyacrylamide gel electrophoresis  as previously described (30). The proteins used for molec- 
ular weight markers were  reduced before  electrophoresis.  They included phosphorylase A, 
molecular weight 94,000  (30) from Sigma Chemical Co. ; bovine albumin, 68,000  (30) from 
Schwarz/Mann, Div. Becton, Dickinson, and Co., Orangeburg, N. J. ; and ovalbumin, 43,000 
(30) from Pharmacia Fine Chemicals Inc., Piscataway, N. J. Human fibrinogen (As-chain, 
70,900; B/3-chain, 60,400; and "~-chain, 49,400)  (31) was provided by Dr. Michael iVfosesson 
and the heavy chain of myosin (212,000)  (32), by Dr. Paul Dreizen, both of the State Uni- 
versity of New York, Downstate Medical Center, Brooklyn, N. Y. 
RESULTS 
Effect of Trypsin on the Subunit Chain Structure  of Human Plasma o~..,-Macro- 
globulin  (Fig. l).--After incubation of trypsin and a2-macroglobulin no altera- 
tion in the band pattern was produced by electrophoresis of unreduced samples 
in SDS-polyacrylamide gels (Fig. 1, gels A  and B). However, a major alteration 
in the band pattern of a2-macroglobulin was evident if the samples were reduced 
before electrophoresis. After reduction of ~x2-macroglobulin which had not been 
reacted  with  enzyme,  one  maj'or  protein  band  with  an  apparent  molecular 
weight  of  185,000  (range  182,000-187,000)  was  identified  (Fig.  1,  gel  C). 
Several minor slowly migrating components remained near the  top  of the gel 
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macroglobulin  had  been  incomplete.  A  new  band,  molecular  weight  85,000 
(range 83,000-87,000),  was observed after incubation with trypsin for 1 h, and 
its  appearance  was accompanied by depletion  of the precursor subunit  chain 
(Fig.  1,  gel D).  Preincubation  of trypsin  with  soybean  or pancreatic  trypsin 
inhibitor prevented  this trypsin-induced alteration in the primary structure of 
a2-macroglobulin. DFP-inactivated trypsin also failed to alter ~2-macroglobulin. 
A  band  corresponding  to  trypsin  was  not observed,  presumably because  the 
amount of enzyme would have been too low to produce a visible protein band 
(the molecular weight of trypsin being }~0 of that of o~2-macroglobulin). 
FIG. 1. SDS-polyacrylamide gel electrophoresis (5% gel) of an incubation  mixture  of an 
equimolar ratio of human plasma a2-macroglobulin and trypsin. Equal volumes of as-macro- 
globulin  (6.9 mg/ml)  and  trypsin  (195 /zg active  enzyme per milliliter) were incubated  at 
37°C. Portions were removed at 0 time and at 1 h and added to an SDS-urea solution (gels 
A, B) or reduced with  a similar solution containing  14 mM dithiothreitol  (gels C, 1)). The 
approximate molecular weights of the bands that were identified after reduction are indicated. 
The Effect of Enzyme Concentration  on the Trypsin-Induced Alteration in the 
Subunit Structure of o~2-Macroglobulin. (Fig. 2).--Trypsin,  incubated  with a2- 
macroglobulin for 1 min before reduction, produced increases in the derivative 
chain  which  were  proportional  to  the  enzyme  concentration  (Fig.  2).  The 
derivative chain that formed appeared within 1 min of incubation. The amount 
formed, as assessed by the densitometric ratio of the precursor to product chain, 
remained  stable  for at  least  an  additional  60 rain incubation  at 37°C.  In the 
molar ratio of 0.15-2.5 tool trypsin relative to 1 mol ~-macroglobulin, only one 
derivative  band  was  observed  after  incubation,  suggesting  that  the  parent 512  O~2-MACROGLOBULIN ENZYME INTERACTIONS 
chain had  been cleaved  at,  or  very near  its  center.  ~ At  a  trypsin-o~-macro- 
globulin molar ratio that approached saturation (1.25) or exceeded the binding 
capacity of a2-macroglobulin for  the:enzym~ (2.5),  a  faster migration of  the 
proteolytic derivative was apparent indicatifig that further degradation of this 
component had occurred (Fig. 2). 
The formation of a single derivative band appears to be dependent not only 
on the amount of trypsin but also upon the functional state of a2-macroglobulin. 
Acidification of a=,-macroglobulin to  pH  2.0  for  30  rain at  37°C  followed by 
FIG. 2.  SDS-polyacrylamide gel electrophoresis (5% gel) after  reduction with  DTT of 
incubation mixtures of increasing concentrations of trypsin and a constant concentration of 
a2-macroglobulin. Equal volumes of ae-macroglobulin (4.8 mg/ml) and buffer or serial dilu- 
tions of trypsin were incubated  1 and 61 min at 37°C (first and second gel of each pair, re- 
spectively), and the  reaction stopped by the addition  of an SDS-urea-DTT  solution. The 
highest concentration of trypsin was 420/~g/ml, corresponding to a trypsin: ae-macroglobulin 
molar ratio of 2.5. 
neutralization, destroyed its capacity to form a complex with trypsin, a finding 
previously reported (26) ; such treatment, however, produced no evident altera- 
tion in its structure as assessed by SDS-polyacrylamide gel electrophoresis of 
reduced samples. After acid treatment o~.,-macroglobulin manifested a  greatly 
increased susceptibility to proteolytic degradation by trypsin since molar ratios 
of trypsin to o~.,-macroglobulin as low as 0.002 degraded oe2-macroglobulin into 
2 There  is a discrepancy between the  calculated molecular weight of the  subunit chain 
(2  X  85,000 =  170,000) and that determined  by SDS-polyacrylamide gel electrophoresis 
(e.g., 185,000). This discrepancy may be due to the anomalous migration of some proteins 
in SDS-polyacrylamide gels (33) or the errors inherent in this method for establishing molec- 
ular weight (34). Alternatively, a small molecular weight fragment or fragments whose pres- 
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multiple protein bands with molecular weights lower than the 85,000 molecular 
weight derivative. 
Effect  of  Thrombin,  Plasmin,  Plasma Kallikrein,  and Chymotrypsin  on  the 
Subuni! Structure  of o~-Macroglobulin  (Figs.  3,  4).--Interaction  of oe2-macro- 
globulin with  each of these  enzymes resulted  in  the formation of a  derivative 
chain manifesting an electrophoretic mobility identical  to the mobility of that 
derivative chain produced in the oz2-macroglobulin-trypsin interaction.  As was 
the  case  with  trypsin,  reduction  of  o~2-macroglobulin  was  necessary  for  the 
FIG. 3.  SDS-polyacrylamide gel electrophoresis  (5%  gel) after  reduction  with  DTT of 
c~2-macroglobulin incubated  with  trypsin,  thrombin,  plasmin,  or plasma  kallikrein.  These 
enzymes were incubated with a2-macroglobulin (165 #g per system) in the following approxi- 
mate molar ratios:  trypsin,  1 (5.4 #g): thrombin,  0.5  (12  NIH units);  plasmin,  0.4  (0.15 
caseinolytic  units);  plasma  kallikrein,  0.7  (0.14 TAMe  esterase  units).  The reaction  was 
stopped  after  1 h  at 37°C and  the mixture  reduced  by the addition  of an SDS-urea-DTT 
solution. 
demonstration  of  the  derivative  band  by  SDS-polyacrylamide  gel  electro- 
phoresis (cf. Fig. 1). Small amounts of material with apparent molecular weights 
greater  than  185,000 were present  in incubation mixtures of o~2-macroglobulin 
with  thrombin  and  plasmin  that  were  not  apparent  in  the  electrophoretic 
patterns produced by the individual  components. The nature of these bands is 
not  known.  Faster  migrating  material  in  the  a2-macroglobulin,  kallikrein 
mixture was due to material added with the enzyme preparation itself. To test 
whether plasmin,  a potential contaminant of thrombin and kallikrein prepara- 
tions, was the active agent, the following experiments were performed. Throm- 
bin was preincubated  with  soybean trypsin inhibitor  and kallikrein  with lima 
bean trypsin inhibitor,  substances  which inhibit plasmin but not the enzymes 514  OL2-MACROGLOBULIN  ENZYME  INTERACTIONS 
themselves  (22,  35).  These  inhibitors  did  not  prevent  the  production  of  the 
derivative  chain  indicating  that  thrombin  and  kallikrein  were  the  enzymes 
responsible for the production of the structural change  in o~2-macroglobulin. 
Chymotrypsin produced a  derivative band with a  molecular weight similar 
to that produced by trypsin (Fig. 4). In addition,  more faintly staining bands 
representing two previously unrecognized cleavage products were also formed. 
Their apparent molecular weights were 90,000  and 75,000,  respectively. 
FIG. 4. SDS-polyacrylamide  gel electrophoresis (9% gel) after reduction with DTT of oe2- 
macroglobulin incubated with chymotrypsin or trypsin. An equal volume of ce._,-macroglobu- 
lin (6.9 mg/ml) was incubated with chymotrypsin (200 Izg/ml) or trypsin  (195/*g/ml) for 
1 h, representing an enzyme to c~,.,-macroglobulin  molar ratio of 1. 
Subunit Structure  of o~._,-Macroglobulin Prepared from Plasma Incubated  with 
Plasminogen  Activator,  Urokinase  (Fig. 5).--The following studies were carried 
out to determine whether the structural alteration in a2-macroglobulin induced 
by incubation  with plasmin in purified systems also occurred in  a  plasma en- 
vironment, oL2-macroglobulin was isolated from plasma incubated with urokinase 
(500 U/ml plasma) as described previously (4). SDS-polyacrylamide gel electro- 
phoresis of this preparation,  after reduction  with dithiothreitol,  demonstrated 
the  85,000  molecular  weight  derivative  chain,  whereas  the  ~2-macroglobulin 
from a portion of the same plasma not incubated with urokinase showed only 
the  parent  chain.  Urokinase  (300  U/ml),  incubated  in  the  absence  of  plas- 
minogen with purified o~-macroglobulin (6.9 mg/ml) for 30 rain at 37°C  failed 
to produce the derivative chain. PETER  C.  HARPEL  515 
DISCUSSION 
This  study  has  shown  that  the  subunit  structure  of  human  plasma  ~- 
macroglobulin is  altered by interaction with proteolytic enzymes that  it  in- 
hibits.  ~-macroglobulin  that  has  not  formed  a  complex  with  proteases  is 
comprised  of  subunit  chains  having  a  molecular  weight  of  approximately 
185,000;  with the exception of chymotrypsin, all the proteases studied attack 
only one region in each subunit chain and produce a  single derivative with a 
molecular weight approximately one-half that of the parent  chain.  This sug- 
gested that the enzyme-susceptible region was located at or near the center of 
Fic.  5.  SDS-polyacrylamide  gel electrophoresis (5% gel) after reduction with DTT of 
c~2-macroglobulin  isolated from plasma incubated 1 h with a plasminogen  activator, urokinase 
or isolated from a portion of the same plasma incubated with buffer. 
the parent chain. On the other hand, chymotrypsin interacted with oz2-macro- 
globulin to yield three derivative chains after reduction indicating that there 
are at least two chymotrypsin susceptible regions in the precursor chain. 
a2-macroglobulin functionally capable  of binding  enzymes appeared  to  be 
required for limiting hydrolytic attack to a specific region of the molecule. The 
concentration dependent increase in derivative chain demonstrated with trypsin 
occurred during the 1st min of incubation. No increase in this product was ob- 
served during an additional hour of incubation indicating that the enzyme was 
completely inhibited by o~2-macroglobulin after the initial proteolytic attack on 
the inhibitor.  In  contrast,  after acid  denaturation,  a2-macroglobulin did  not 
bind trypsin and became extremely susceptible to trypsin-induced degradation, 
being hydrolyzed into multiple low molecular weight products. 516  OL2-MACROGLOBULIN  ENZYME  INTERACTIONS 
Hydrolysis of a._,-macroglobulin  accompanied its interaction with proteases 
but the data do not permit a conclusion as to whether this particular reaction 
was  necessary for  the  formation  of  the  enzyme-a2-macroglobulin  complex. 
This alteration in the structure of a2-macroglobulin appears to be analogous to 
the structural changes which occur when tr)~sin interacts with soybean trypsin 
inhibitor, as well as with a variety of other protein trypsin inhibitors of non- 
human, nonplasma origin (16). Laskowski and co-workers (36, 37) have demon- 
strated  that  the  trypsin  inhibitor interaction is  accompanied by proteolytic 
cleavage at a single arginine or lysine residue in the inhibitor located within a 
peptide loop formed by intrachain  disulfide bridging. Several different mech- 
anisms have been suggested to explain the nature of the association  between 
trypsin  and  its protein  inhibitors.  Laskowski  has  suggested  that  a  covalent 
bond is formed between  enzyme and  inhibitor  involving an  acyl-enzyme or 
tetrahedral  intermediate in  which  the  active site  serine  of trypsin forms an 
ester bond with the carboxyl of the arginine or lysine reactive site of the in- 
hibitor (16). In this reaction the catalytic activity of trypsin is completely in- 
hibited.  A  contrasting  theory has  been proposed by Feeney and  co-workers 
who have contended that peptide bond cleavage may be unnecessary for in- 
hibition of trypsin by its inhibitors (38). Regardless of which view proves cor- 
rect, it is unlikely that a covalent bond is formed between the active site of the 
enzyme and a2-macroglobulin since the complex retains enzymic activity. 
Nonetheless, peptide bond cleavage may well be a requirement for formation 
of the a._,-macroglobulin-enzyme complex since a proteolytic step appears to be 
necessary for this reaction. Whereas plasmin formed a complex with a2-macro- 
globulin, neither plasminogen nor DFP-inactivated plasmin were found to do so 
(39). Furthermore, in unpublished gel sieving experiments, more than 85 % of 
an 12'~'I-labeled trypsin preparation (molecular weight 24,000)  was eluted with 
purified a2-macroglobulin as a high molecular weight complex, whereas less than 
5%  of  an  12~I-labeled DFP-inactivated  trypsin  preparation  eluted  with  a2- 
macroglobulin.  Thus,  complex  formation  required  the  enzymic  active  site. 
These investigations parallel prior studies which suggested that the ability of 
plasmin to alter both the functional and immunoelectrophoretie properties of 
C1 inactivator, an inhibitor of plasmin as well as several other plasma enzymes, 
was due to the proteolytic activity of the enzyme (40). 
Jones et  al.  (41)  studied  a,_,-macroglobulin  isolated from plasma  by ultra- 
centrifugal techniques and concluded that the molecular weight of its subunit 
chain after reduction was 196,000. This molecular weight is in close agreement 
to  the  one  found  in  this  study  by  SDS-polyacrylamide gel  electrophoresis 
utilizing a=,-macroglobulin  also prepared from plasma.  These values stand  in 
sharp  contrast to the results of Frdnov et al.  (42)  who found that  85 %  of a 
reduced sample of a..,-macroglobulin  isolated from serum had a molecular weight 
of 83,000; the remaining 15 % had a molecular weight of 190,000. The present 
study provides an explanation for this disparity in the molecular weight esti- PEW~g e.  ~ARPEL  517 
mates of the subunit chains of oz~-macroglobulin (viz., 196,000 vs. 83,000).  The 
lower molecular weight  chain  observed by Fr6noy et  al.  corresponds  to  the 
derivative  chain  identified  in  samples  of  o~2-macroglobulin  complexed  with 
proteases in experiments performed with purified components or from plasma 
activated  with  urokinase.  It is  likely that  the structure  of serum a o-macro- 
globulin is a consequence of its interaction with enzymes like thrombin, plasmin, 
and kallikrein  which are activated during the conversion of plasma  to serum 
(43-47). 
The  data obtained  in  this  study suggest a  possible  model for the  subunit 
structure of a2-macroglobulin (Fig. 6). It has been shown that a2-macroglobulin 
NH2  COOH  NH  2  COOH  NH2  COOH  NH  2  COOH 
S  S  ........  _  S  S 
Molecular ~  ~  I  ~  ~-J 
weight:  680,000  J 
\~psin,i/plasmin, thrombin,  kallikrein 
coo   i o0  i00  I  /   s_sM  /  LD,su,,ide  >  '+  + 
U  ~S--SI  Ib°ndcleavage 
COOH  NH2_~  2  COOH  NH2J  2 
Molecular  weight: 185,000  85,000  85,000 
(subunit chain) (proteolyti¢  derivative) 
FlO. 6. A diagrammatic model of the proposed subunit structure of human plasma a2- 
macroglobulin indicating the modification induced in the molecule by interaction with pro- 
teases. The placement of the NH2-terminal and C-terminal ends of the subunit chains is 
arbitrary and the minimum number of inter- and intrachain disulfide bridges is indicated. 
The half-molecules of o~2-macroglobulin are  held together by noncovalent bonds (dashed 
lines). In the model shown, one-half of the precursor subunit chains have been cleaved. 
dissociated into half-molecules at acid pH or in the presence of urea suggesting 
that  the  protein  has  a  noncovalently linked  dimeric  structure  (41,  48T50). 
Prior studies have estimated the molecular weight of ae-macroglobulin to be in 
the order of 650,000  (51) or 725,000 (41). The molecule must necessarily consist 
of four Chains since each subunit chain formed after reduction has a molecular 
weight of 1851000;  each half-molecule, therefore,  is comprised of two subunit 
chains linked by disulfide  bridges. The derivative subunit chains resulting from 
the o~2-macroglobulin-protease  interaction were identified only after reduction 
of the a2-macroglobulin preparations  indicating  that  they were linked  to  the 
parent molecule by both intra- and interchain disulfide  bonds. This conclusion 
is based in part upon the assumption that each of the four subunit chains is 518  ~2-MACROGLOBULIN ENZYME INTERACTIONS 
essentially identical. These data indicate that a  total of eight such derivative 
products can be formed per molecule ~x2-macroglobulin. 
Prior studies have indicated that plasma  proteases may be activated  and 
bound to ~z2-macroglobulin  during the procedures involved in blood collection 
and protein purification unless appropriate precautions are employed (4, 8). In 
addition, recent evidence has suggested that a portion of circulating a2-macro- 
globulin may be complexed with a plasmin-like proteolytic enzyme (4). Thus, 
the finding of six different NH2-terminal amino acids associated with purified 
a2-maeroglobufin (50) may be due not only to the subunit chain structure of the 
protein, but also to the bound enzyme(s) as well as to new NH2-terminal amino 
acids produced by proteolysis. 
This study has demonstrated that a2-macroglobulin acts as a  substrate for 
circulating proteases and raises the possibility that other plasma inhibitors may 
interact with the enzymes they inhibit in a similar manner. These findings pro- 
vide new information regarding the nature of a~-macroglobulin,  a  circulating 
modulator of the coagulation, fibrinolytic, and kallikrein enzyme systems. 
SUMMARY 
Human plasma a~-macroglobulin is an inhibitor of circulating proteases that 
function in hemostatic and inflammatory reactions but the biochemical nature 
of its interaction with these enzymes is not well defined. This investigation has 
found that a2-macroglobulin is comprised of subunit chains of 185,000 molecular 
weight as analyzed by electrophoresis in polyacrylamide gels containing sodium 
dodecyl sulfate. Trypsin, thrombin, plasmin, and plasma kallikrein in amounts 
completely bound to ~2-macrogiobulin attacked one region in the subunit chain 
producing a single derivative with a molecular weight of 85,000 indicating that 
hydrolysis occurred at or near the center of the parent chain. The proteolytic 
derivative was also identified in an o~2-macroglobulin preparation from plasma 
incubated with  the plasmlnogen activator, urokinase. ~-macroglobulin func- 
tionally capable of binding enzyme appeared to be required both for limiting 
tryptic hydrolysis and for confining the concentration dependent increase in the 
derivative chain to the  1st rain of incubation since acid-denatured ~-macro- 
globulin that failed to bind trypsin was extensively degraded. Three derivative 
chains  resulted from the  interaction of ~2-macroglobulin with  chymotrypsin 
demonstrating the presence of at least two chymotrypsin susceptible regions in 
the precursor chain.  Reduction of the ~2-macroglobulin-enzyme mixture was 
required for the identification of the derivative subunit chains establishing that 
these cleavage products were covalently linked to the parent molecule by disul- 
fide bridges. Thus, o~2-macroglobulin acts as a substrate for circulating proteases, 
a finding which may also pertain to the mechanism of action of other plasma 
enzyme inhibitors. 
These studies were performed with the skilled  technical assistance of Mr. Tsun-San Chang 
and Mrs. Angela Howard. Doctors Ralph Nachman and Michael Mosesson kindly reviewed 
this manuscript and made valuable suggestions. PETER C.  HARPEL  519 
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